Geron Corp. (GERN)

4.09
0.15 3.80
NASDAQ : Health Technology
Prev Close 3.94
Open 3.97
Day Low/High 3.92 / 4.16
52 Wk Low/High 1.74 / 6.68
Volume 3.90M
Avg Volume 4.38M
Exchange NASDAQ
Shares Outstanding 183.62M
Market Cap 719.80M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting GERN Put And Call Options For August 17th

Interesting GERN Put And Call Options For August 17th

Investors in Geron Corp. saw new options become available this week, for the August 17th expiration.

Interesting GERN Put And Call Options For July 20th

Investors in Geron Corp. saw new options become available this week, for the July 20th expiration.

Box, Applied Materials, Goodyear: 'Mad Money' Lightning Round

Box, Applied Materials, Goodyear: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Box, Applied Materials, Goodyear, Geron, Cognex, Jacobs Engineering, Editas Medicine.

Unreasonable Expectations: Cramer's 'Mad Money' Recap (Tuesday 5/1/18)

Unreasonable Expectations: Cramer's 'Mad Money' Recap (Tuesday 5/1/18)

Expectations about earnings are totally out of whack, says Jim Cramer. Will Apple's earnings break the spell?

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Geron Corporation

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Geron Corporation

Levi & Korsinsky announces it has commenced an investigation of Geron Corporation ("Geron" or "the Company") (NASDAQGS: GERN) concerning possible violations of federal securities laws.

GERON CORPORATION INVESTOR ALERT: Girard Gibbs Investigates Potential Securities Law Violations

GERON CORPORATION INVESTOR ALERT: Girard Gibbs Investigates Potential Securities Law Violations

Girard Gibbs LLP is investigating claims on behalf of investors of Geron Corporation (NASDAQ:GERN) involving possible securities law violations.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Geron Corporation - GERN

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Geron Corporation - GERN

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Geron Corporation (NASDAQ: GERN) resulting from allegations that Geron may have...

First Week Of May 18th Options Trading For Geron (GERN)

First Week Of May 18th Options Trading For Geron (GERN)

Investors in Geron Corp. saw new options begin trading this week, for the May 18th expiration.

Geron Corporation Reports Fourth Quarter And Annual 2017 Financial Results And Recent Events

Geron Corporation Reports Fourth Quarter And Annual 2017 Financial Results And Recent Events

Conference Call Scheduled for 8:30 a.m. ET on Monday, March 19

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-cap stocks have finally jumped back to life on prospects for a strong U.S. economy this year. What trade war?

Geron To Host Analyst And Investor Meeting And Webcast On December 19, 2017

Geron To Host Analyst And Investor Meeting And Webcast On December 19, 2017

Management to be joined by external guest speaker to review imetelstat data from IMerge to be presented at the 59th American Society of Hematology Annual Meeting and Exposition

Geron Announces Presentations At American Society Of Hematology Annual Meeting

Geron Announces Presentations At American Society Of Hematology Annual Meeting

Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers

The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.

Geron Announces Fast Track Designation Granted To Imetelstat For Lower Risk Myelodysplastic Syndromes

Geron Announces Fast Track Designation Granted To Imetelstat For Lower Risk Myelodysplastic Syndromes

Expanded Part 1 of IMerge is Open for Patient Enrollment

TheStreet Quant Rating: D+ (Sell)